AI Article Synopsis
- Developing nanocarriers for targeted delivery of medications to tumors represents a promising advancement in cancer treatment amidst challenges posed by cancer's complex environment.
- Artificial antigen presenting cells (aAPCs) are innovative devices that help activate T lymphocytes to fight cancer by mimicking natural cells and providing necessary signals.
- Key design factors for aAPCs include their size, shape, and protein distribution, with an emphasis on ensuring effective contact with T cells to enhance activation and treatment efficacy.
Article Abstract
Developing nanocarriers that can carry medications directly to tumors is an exciting development in cancer nanomedicine. The efficacy of this intriguing therapeutic approach is, however, compromised by intricate and immunosuppressive circumstances that arise concurrently with the onset of cancer. The artificial antigen presenting cell (aAPC), a micro or nanoparticle based device that mimics an antigen presenting cell by providing crucial signal proteins to T lymphocytes to activate them against cancer, is one cutting-edge method for cancer immunotherapy. This review delves into the critical design considerations for aAPCs, particularly focusing on particle size, shape, and the non-uniform distribution of T cell activating proteins on their surfaces. Adequate surface contact between T cells and aAPCs is essential for activation, prompting engineers to develop nano-aAPCs with microscale contact areas through techniques such as shape modification and nanoparticle clustering. Additionally, we explore recommendations for future advancements in this field.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijpharm.2024.125053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Prototype of Ultrasensitive Time-Resolved Fluoroimmunoassay with Enhanced Fluorescence System for the Trace Determination of Urinary 8-Hydroxy-2`-Deoxyguanosine, the DNA Oxidative Stress Biomarker.
J Fluoresc
January 2025
Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, Phayathai Road Pathumwan, 10330, Thailand.
This study presents a new highly sensitive and specific time-resolved fluoroimmunoassay (TRFIA) for the measurement of trace amounts of the urinary 8-hydroxy-2`-deoxyguanosine (8-OHdG) which is a biomarker for oxidative stress on DNA. The assay relied on a competitive binding approach and a mouse monoclonal antibody which recognized 8-OHdG with high specificity. In this assay, 8-OHdG conjugated with bovine serum albumin protein (8-OHdG-BSA) was employed as a solid phase antigen.
View Article and Find Full Text PDFSerum assisted PD-L1 aptamer screening for improving its stability.
Sci Rep
January 2025
School of Public Health, Jining Medical University, Jining, 272067, People's Republic of China.
Aptamers have shown potential for diagnosing clinical markers and targeted treatment of diseases. However, their limited stability and short half-life hinder their broader applications. Here, a real sample assisted capture-SELEX strategy is proposed to enhance the aptamer stability, using the selection of specific aptamer towards PD-L1 as an example.
View Article and Find Full Text PDFExploring the comorbidity mechanisms between atherosclerosis and hashimoto's thyroiditis based on microarray and single-cell sequencing analysis.
Sci Rep
January 2025
Cardiology Department, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China.
Atherosclerosis (AS) is a chronic vascular disease characterized by inflammation of the arterial wall and the formation of cholesterol plaques. Hashimoto's thyroiditis (HT) is an autoimmune disorder marked by chronic inflammation and destruction of thyroid tissue. Although previous studies have identified common risk factors between AS and HT, the specific etiology and pathogenic mechanisms underlying these associations remain unclear.
View Article and Find Full Text PDFPromotion of Triple Negative Breast Cancer Immunotherapy by Combining Bioactive Radicals with Immune Checkpoint Blockade.
Acta Biomater
January 2025
Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China, 610041. Electronic address:
Although immunotherapy has revolutionized clinical cancer treatment, the efficacy is limited due to the lack of tumor-associated antigens (TAAs) and the presence of compensatory immune checkpoints. To overcome the deficiency, a nano-system loaded with ozone and CD47 inhibitor RRx-001 is designed and synthesized. Upon irradiation, reactive oxygen species (ROS) generated from ozone reacts with nitric oxide (NO) metabolized from RRx-001 to form reactive nitrogen species (RNS), which presents a much stronger cell-killing ability than ROS.
View Article and Find Full Text PDFDiscovery and exploration of adaptive immune response-related drug targets in diabetic retinopathy by Mendelian randomization.
Diabetes Res Clin Pract
January 2025
Department of Ophthalmology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China. Electronic address:
Background: Persistent diabetes raises diabetic retinopathy (DR) risk, and management is challenging. Integrating transcriptomics and MR, this study provides a current reference for the clinical treatment of DR by identifying potential drug targets in adaptive immune response-associated genes (AIR-RGs).
Methods: The GSE102485 dataset about AIR-RGs and DR was downloaded from a public database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!